20Oct 2023 by Andrew Premovich

New antibody shows strong potential against pancreatic cancer

Press Releases, Uncategorized
SIWA318H specifically targets and removes senescent cells in pancreatic tumors, slowing their growth PHOENIX, AZ — Oct. 12, 2023  — Scientists at the Translational Genomics Research Institute (TGen), part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product (AGE)-targeting antibody, in the fight against pancreatic cancer. The results appear in Scientific Reports, a Nature publication. Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), has long been known for its aggressive nature and resistance to current treatment options. SIWA318H’s ability to selectively target senescent cells represents a new approach to treating the disease. Senescent cells within the tumor microenvironment have been identified as major contributors to tumor development, growth and therapy resistance. SIWA318H, an antibody specifically designed to target AGEs, offers…
Read More
14Mar 2022 by Andrew Premovich

SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study

Uncategorized
CHICAGO, March 14, 2022 -- PRNewswire -- SIWA Therapeutics, Inc. (“SIWA”), a Chicago-based biopharmaceutical company announced today that SIWA’s proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer. The study was conducted by the Translational Genomics research Institute (“TGEN”), pursuant to a SIWA-sponsored research agreement. Results of the pancreatic cancer study in humanized mice treated with SIWA318H included: Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by significantly reducing tumor growth (P-Value < 0.0001); There was a significantly higher number of complete remission cases in the treated groups compared to the isotype-treated control group. 37.5% (6 out of 16 mice) treated with SIWA318H high dose had…
Read More
14Oct 2020 by Andrew Premovich

In The News: Supertrends

In The News
SIWA CEO and Chief Scientific Officer, Lewis Gruber, was featured in a recent interview with Supertrends where he discussed how SIWA 318H targets cancerous, senescent, and virally infected cells. Read the full interview here: https://www.supertrends.com/senolytics-showcase-link-between-life-extension-and-therapeutics/
Read More
08Oct 2020 by Andrew Premovich

In The News: Startup.info Interview

In The News
"While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases." In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug. Read the full interview here: https://startup.info/lewis-gruber-siwa-therapeutics/
Read More
02Jun 2020 by Andrew Premovich

In The News: 1000 Longevity Leaders

In The News
We are pleased to announce that Lewis Gruber was recently named to the Aging Analytics Agency’s list of 1000 Longevity Leaders recognized in the research and academia sector for his work with SIWA Therapeutics. Aging Analytics is the longest-running and most comprehensive interactive platform of longevity professionals. The agency profiles public and private-sector influencers whose work in business, science, policy, philanthropy, or thought-leadership is instrumental in the longevity landscape.
Read More